Navigation Links
Arpida Annual General Meeting of Shareholders Approves All Board Proposals
Date:5/7/2009

REINACH, Switzerland, May 7 /PRNewswire-FirstCall/ -- The Annual General Meeting of Arpida Ltd (SIX: ARPN) has approved the proposals that were put forward by the Board of Directors.

A total of 90 shareholders were present at the meeting that took place in Reinach today. 4,629,711 shares were represented, or 21.9% of the total number of shares issued (21,094,104).

The following items were on the agenda.

1. Information on strategic options

There was a lively discussion regarding the possible strategic scenarios as presented by the CEO, Dr Jurgen Raths. An overview of these scenarios was already published in a press release earlier today. Shareholders provided valuable comments that will be incorporated in the further strategic evaluation. No decision was taken yet. The Board of Directors assured the shareholders that they will be duly involved in any major strategic decision.

2. Approval of the 2008 Business Report, Company Accounts and Group Accounts

The shareholders approved the 2008 Business Report, comprising the annual financial statements, the consolidated accounts and the 2008 Annual Report.

3. Discharge of the Board of Directors and of the Senior Executive Officers

The shareholders granted discharge to the Board of Directors and to the Senior Executive Officers for their actions.

4. Compensation of Losses with General Reserves

The shareholders approved the Board proposal to compensate the accumulated loss of CHF 189,591,477 with an equal amount of share premium in the general reserves.

5. Re-election of the Auditors

The shareholders re-elected PricewaterhouseCoopers Ltd as Auditors for 2009.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

    Contacts:
    Dr Jurgen Raths, President and CEO
    Tel.: +41-61-417-96-60

    Harry Welten, MBA, CFO and Senior Vice President
    Tel.: +41-61-417-96-65

    Paul Verbraeken, Head of Corporate Communications
    Tel.: +41-61-417-96-83



'/>"/>
SOURCE Arpida Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Arpida Interim Results for six Months to 30 June 2007
2. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
3. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
4. Arpida Presents Preclinical Data on AR-2474 at ICAAC
5. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
6. Arpida-Supported CME Symposium Available Online
7. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
8. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
9. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
10. Arpida Announces Full Year 2007 Financial Results
11. Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Ky. and HOUSTON ... Inc. ("NX Prenatal") today announced the formation of ... together leading clinicians and industry veterans who enhance ... company as it accelerates development of its novel ... to provide medical, clinical and strategic guidance for ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... of product vigilance software to leading biopharmaceutical and medical device manufacturers and regulators, ... a fully 21 CFR Part 11-compliant email client designed to provide product vigilance ...
(Date:1/19/2017)... ... 18, 2017 , ... The American Medical Informatics Association (AMIA) ... Sharing Policy. Specifically, the nation’s leading informatics experts, said data sharing plans should ... AMIA recommended that NIH earmark funding for researchers to produce and execute data ...
(Date:1/19/2017)... NEW YORK , Jan. 18, 2017 /PRNewswire/ ... expected to reach USD 92.9 billion by 2025, ... Research, Inc. Pharmaceutical industry has been adaptive of ... functions as early as 2002. Among the services ... the forerunners. For instance, Johnson & Johnson was ...
Breaking Biology Technology:
(Date:12/16/2016)... 16, 2016 The global wearable medical device market, in ... 2021 from USD 5.31 billion in 2016, at a CAGR of ... ... technological advancements in medical devices, launch of a growing number of ... connectivity among healthcare providers, and increasing focus on physical fitness. ...
(Date:12/15/2016)... Mich. , Dec. 15, 2016  There is ... car doors or starting the engine. Continental will demonstrate ... Las Vegas . Through the combination ... Start and Entry) and biometric elements, the international technology ... of vehicle personalization and authentication. "The integration ...
(Date:12/7/2016)... to a new market research report "Emotion Detection and Recognition Market by Technology ... End User, And Region - Global Forecast to 2021", published by MarketsandMarkets, the ... USD 36.07 Billion by 2021, at a Compound Annual Growth Rate (CAGR) of ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):